CDMO ten23 health® (Basel, Switzerland) has announced a manufacturing collaboration to support the commercialization of the BD Libertas™ wearable injector. The collaboration will offer biopharma companies supply chain readiness of a fully integrated, ready-to-use solution for the subcutaneous delivery of large-volume drugs, helping speed development and reduce risk in complex injectable programs.
The collaboration includes the BD Libertas™ wearable on-body injector (OBI) with a 5 ml or 10 ml BD glass cartridge, supported by ten23 health’s process development, aseptic filling, assembly, and quality control services. This setup enables pharmaceutical partners to leverage the BD Libertas™ wearable Injector platform and ten23 development and manufacturing services to bring high-volume subcutaneous treatments to the clinic and market, maintaining flexibility and adequate patient usability.
ten23’s recently announced Line 0 will enable pharmaceutical customers to test cartridge compatibility, perform stability studies, and optimize filling and stopper setting processes under fully representative conditions, without the delays or costs of GMP production. This enables a faster and more informed path to scale-up.
The BD Libertas™ Wearable Injector offers a ready-to-use, wearable injector for subcutaneous administration of high-dose biologics—enabling pharma to transition biologics from IV to SC delivery with potential for a positive patient experience. By combining BD platform technology with ten23 integrated services, BD and ten23 health aim to enable supply chain readiness to support commercialization and support smoother regulatory pathways.
https://www.ten23.health/introducing/press-releases
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
